ArticleDermatology and therapy2020

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.

Craig Leonardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.